ABEONA THERAPEUTICS INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $5.8M | — | $3.5M | $1.4M | $3.0M | $10.0M | — |
| Cost of Revenue | — | $1.5M | — | — | — | — | — | — |
| Gross Profit | — | $4.3M | — | — | — | — | — | — |
| Gross Margin | — | 73.7% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $26.8M | $34.4M | $31.1M | $29.0M | $38.7M | $30.1M | $48.6M |
| SG&A Expense | — | $65.0M | $29.9M | $19.0M | $17.3M | $21.6M | $23.8M | $20.7M |
| Operating Income | — | $-89.4M | $-64.2M | $-47.1M | $-50.9M | $-89.8M | $-81.4M | $-77.1M |
| Operating Margin | — | -1,536.9% | — | -1,346.7% | -3,600.8% | -2,994.5% | -814.2% | — |
| Interest Expense | — | $3.7M | $4.2M | $418.0K | $736.0K | $3.7M | $4.1M | — |
| Pretax Income | — | $71.3M | $-63.7M | — | — | — | — | — |
| Income Tax Expense | — | $100.0K | — | — | — | — | — | — |
| Net Income | — | $71.2M | $-63.7M | $-54.2M | $-39.7M | $-84.9M | $-84.2M | $-76.3M |
| Net Margin | — | 1,223.1% | — | -1,548.2% | -2,807.4% | -2,831.2% | -842.3% | — |
| EPS (Basic) | — | $1.34 | $-1.55 | $-2.53 | $-1.84 | $-7.19 | $-0.30 | $-0.50 |
| EPS (Diluted) | — | $1.01 | $-1.55 | $-2.53 | $-1.84 | $-0.29 | $-0.30 | $-0.50 |
| Shares Outstanding (Basic) | 57.0M | 53.0M | 41.0M | 21.4M | 23.6M | 11.8M | 288.4M | 250.9M |
| Shares Outstanding (Diluted) | 57.0M | 66.1M | 41.0M | 21.4M | 23.6M | 11.8M | 288.4M | 250.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |